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Available online 25 April 2021Assessing the efficacy of a new antiviral drug usually starts with in
vitro studies, continues with in vivo animal studies, and ends with
studies in humans. Each of these three levels has its own rules and
logic, but the three together constitute a comprehensive and coher-
ent step-by-step program which allows the most promising drugs to
be prioritized for well-designed clinical trials, and eventually produ-
ces strong evidence of their efficacy and safety before their use is
recommended on a large scale.
The method is consistent but it takes time, and in a dangerous
outbreak time is crucial. Repurposing a drug used previously for
other diseases in humans can save time because the efficacy of
the drug can be targeted right from the start, its toxicity and
pharmacokinetic (PK) parameters being already well known. The
study can therefore move straight on from evidencing activity in
cells to efficacy trials in humans, bypassing the intermediate
phases of animal studies and human phase II studies centering on
tolerance and PK.
In early 2020, hospitals in many regions were overwhelmed by
the exponentially growing influx of patients with COVID-19. In this
worrying context, repurposing drugs with in vitro activity against
SARS-CoV2 seemed the quickest way to improve COVID-19 care [1].
Some countries included repurposed drugs in their standard of care
from the outset, without waiting for further clinical evidence [2].
Many research teams decided to include repurposed drugs in efficacy
trials without waiting for further preclinical evidence. In this issue of
EBioMedicine, Liesenborghs et al. report how they put the cart along-
side the horse and decided to study the efficacy of itraconazole (a
long-known antifungal drug which they identified as having in vitro
activity against SARS-CoV-2) in both SARS-CoV2-infected hamstersDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2021.103288.
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that itraconazole had no in vivo efficacy in hamsters despite appropri-
ate lung exposure, they stopped the trial in humans.
This approach was coherent at the time. The study was well-con-
ducted and provided a clear answer to a clinical question. It also
makes us wonder which method to adopt next time, when some
other dangerous disease prompts a rapid assessment of the efficacy
of promising drugs.
The history of infectious diseases teaches us that many drugs
showing in vitro activity on non-specific cells eventually prove inef-
fective in treating the disease in humans [4,5]. Since the beginning of
the COVID-19 pandemic, dozens of drugs have been upheld as show-
ing in vitro activity against SARS-CoV-2 [6]. Running efficacy trials on
all these drugs was not the solution, for two reasons.
First, large efficacy trials require time, money and effort. For drugs
expected to have antiviral action, the effort required is even greater
since outpatient trials have to be organized in order to start treat-
ment as soon as possible after the onset of symptoms. Since the over-
all research system is more efficient at deploying hospital trials, the
number of outpatient COVID-19 trials to date has remained low and
cannot provide answers for all the drugs that show potential benefits
in vitro [7,8].
Second, giving sick patients a drug that, with strong probability, is
likely to prove ineffective raises ethical issues. Even if the drug is
known to be well-tolerated, and even if the trial is as adaptive as pos-
sible and includes rules for stopping for futility, where do we draw
the line between a risky gamble and the genuine ambivalence which
justifies to conduct a randomized trial? Is it fair to expose people to a
drug we know well, to assess its efficacy for treating a disease we do
not know well, without first obtaining sufficient pre-clinical evidence
for its activity?
The answer is likely to be "yes, but only if..." The conditions
implied in this "if" include the existence of a high level of threat, a
good tolerance profile and in vitro findings that suggest the drug may
have significant antiviral activity at a dose that can be given to
humans. Liesenborghs et al. suggest an additional condition: when
an emergency trial is launched without all the preclinical prerequi-
sites being available, a preclinical research program should be
launched in parallel to ensure these prerequisites are made available
as soon as possible.r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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